Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,319.23 -2.18 (-0.04%) Dow
39,841.77 -31.22 (-0.08%) Nasdaq
16,822.58 -10.05 (-0.06%) Bitcoin USD
70,245.15 +529.21 (+0.76%) CMC Crypto 200
1,521.90 -4.52 (-0.30%)
CADL May 2024 5.000 put
| Previous close | 0.2500 |
| Open | 0.2500 |
| Bid | 0.0000 |
| Ask | 2.6500 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.2500 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 64 |
GlobeNewswireCandel Therapeutics to Present at the Jefferies Global Healthcare Conference
NEEDHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 5:30 p.m. ET. A live webcast of the pres
- GlobeNewswire
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLCNEEDHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced it will be hosting a webcasted R&D breakfast panel featuring prominent scientific and medical th
- GlobeNewswire
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancerPhase 2 topline overall survival data for CAN-2409 in non-small cell lung cancer (NSCLC), to be presented at ASCO on June 3, 2024On track for topline disease-free survival data from CAN-2409 phase 3 clinical trial in localized intermediate/high risk prostate cancer, expected in Q4 2024 NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Can
